SOUTH PLAINFIELD, NJ, UNITED STATES, 24th October 2024 Admera Health LLC, a leading Next Generation Sequencing (NGS) service provider advancing genetic research, today announced its acquisition of BioEcho Life Sciences GmbH, a Cologne, Germany-based company specializing in innovative DNA and RNA extraction technologies. BioEcho’s intellectual property includes EchoLUTION technology, a one-step extraction process that simplifies and enhances the yield and purity of DNA and RNA.
This strategic acquisition strengthens Admera Health’s capabilities in genomics and expands its global footprint. Combining Admera Health’s expertise in handling difficult-to-sequence samples with BioEcho’s cutting-edge extraction solutions will enhance benefits for a wide range of applications.
“Our acquisition of BioEcho is a pivotal step in Admera Health’s growth,” said Yun Zhao, CEO of Admera Health. “We are committed to providing our customers with the most advanced technologies. BioEcho’s EchoLUTION platform perfectly complements our NGS services, and together, we will be better equipped to support our customers’ research needs.”
The acquisition also offers significant synergies, particularly given the companies’ overlapping customer bases, which span industries such as infectious disease research, agricultural biotechnology, pharmaceutical development, and academic research. With the addition of BioEcho’s capabilities, Admera Health is well-positioned to expand its NGS-based services across Europe.
BioEcho will continue to operate under its own name, focusing on serving its non-North American customers. In North America, Admera Health will assume the role previously held by BioEcho’s subsidiary, offering EchoLUTION extraction both as a service and as a standalone product.
This acquisition underscores Admera Health’s commitment to delivering innovative solutions that drive worldwide advancement in genetic-based research.
